Review





Similar Products

atcc 29212 vancomycin  (ATCC)
99
ATCC atcc 29212 vancomycin
Atcc 29212 Vancomycin, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atcc 29212 vancomycin/product/ATCC
Average 99 stars, based on 1 article reviews
atcc 29212 vancomycin - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
vancomycin  (MedChemExpress)
95
MedChemExpress vancomycin
Vancomycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vancomycin/product/MedChemExpress
Average 95 stars, based on 1 article reviews
vancomycin - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
vancomycin hy b0671  (MedChemExpress)
95
MedChemExpress vancomycin hy b0671
Vancomycin Hy B0671, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vancomycin hy b0671/product/MedChemExpress
Average 95 stars, based on 1 article reviews
vancomycin hy b0671 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
vancomycin staphylococcus aureus atcc 29213  (ATCC)
99
ATCC vancomycin staphylococcus aureus atcc 29213
Vancomycin Staphylococcus Aureus Atcc 29213, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vancomycin staphylococcus aureus atcc 29213/product/ATCC
Average 99 stars, based on 1 article reviews
vancomycin staphylococcus aureus atcc 29213 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
vancomycin resistant enterococcus faecalis  (ATCC)
94
ATCC vancomycin resistant enterococcus faecalis
Vancomycin Resistant Enterococcus Faecalis, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vancomycin resistant enterococcus faecalis/product/ATCC
Average 94 stars, based on 1 article reviews
vancomycin resistant enterococcus faecalis - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
vancomycin resistant enterococcus faecium  (ATCC)
95
ATCC vancomycin resistant enterococcus faecium
Examination of cell membrane permeability in VanA VRE (E. <t>faecium</t> BAA-2317) induced by compounds 1 and 2 (no induced permeability) versus 9a (induced permeability) at 10 μM (added at 5 min). Cell envelop permeability is indicated by an increase in fluorescence resulting from propidium iodide (PI) influx following compound administration.
Vancomycin Resistant Enterococcus Faecium, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vancomycin resistant enterococcus faecium/product/ATCC
Average 95 stars, based on 1 article reviews
vancomycin resistant enterococcus faecium - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
linezolid lzd  (MedChemExpress)
95
MedChemExpress linezolid lzd
Planktonic cells of MSSA SA113 (A) and MRSA YUSA145 (B) were treated with 1/16×, 1/8×, 1/4×, 1/2×, 1× MIC of LLY-507. The LLY-507 MIC for these S. aureus clinical isolates was 25 μM. The OD 600 of the bacterial cells was then measured by Bioscreen C (Turku, Finland) at 1-h intervals for 24 h. TSB without antimicrobials was used as the untreated control. Data are shown as mean ± SD, n = 3. Time-killing curve of LLY-507 against clinical MRSA (YUSA145) and the impact of LLY-507 on the growth curves of S. aureus planktonic cells. Bacterial cultures in the logarithmic growth phase (OD 600 = 0.6–0.8) were treated with 2× MIC of LLY-507, Vancomycin (Van), and <t>Linezolid</t> <t>(LZD)</t> separately (C). Bacterial cultures in the stationary phase (OD 600 > 3) were treated with 2× MIC of LLY-507, Vancomycin, and Linezolid, followed by overnight incubation (D). Bactericidal curves were plotted accordingly.
Linezolid Lzd, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/linezolid lzd/product/MedChemExpress
Average 95 stars, based on 1 article reviews
linezolid lzd - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
staphylococcus aureus atcc 700698 vancomycin hvisa  (ATCC)
97
ATCC staphylococcus aureus atcc 700698 vancomycin hvisa
Planktonic cells of MSSA SA113 (A) and MRSA YUSA145 (B) were treated with 1/16×, 1/8×, 1/4×, 1/2×, 1× MIC of LLY-507. The LLY-507 MIC for these S. aureus clinical isolates was 25 μM. The OD 600 of the bacterial cells was then measured by Bioscreen C (Turku, Finland) at 1-h intervals for 24 h. TSB without antimicrobials was used as the untreated control. Data are shown as mean ± SD, n = 3. Time-killing curve of LLY-507 against clinical MRSA (YUSA145) and the impact of LLY-507 on the growth curves of S. aureus planktonic cells. Bacterial cultures in the logarithmic growth phase (OD 600 = 0.6–0.8) were treated with 2× MIC of LLY-507, Vancomycin (Van), and <t>Linezolid</t> <t>(LZD)</t> separately (C). Bacterial cultures in the stationary phase (OD 600 > 3) were treated with 2× MIC of LLY-507, Vancomycin, and Linezolid, followed by overnight incubation (D). Bactericidal curves were plotted accordingly.
Staphylococcus Aureus Atcc 700698 Vancomycin Hvisa, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/staphylococcus aureus atcc 700698 vancomycin hvisa/product/ATCC
Average 97 stars, based on 1 article reviews
staphylococcus aureus atcc 700698 vancomycin hvisa - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
enterococcus faecalis atcc 51299 vancomycin vanb  (ATCC)
99
ATCC enterococcus faecalis atcc 51299 vancomycin vanb
Planktonic cells of MSSA SA113 (A) and MRSA YUSA145 (B) were treated with 1/16×, 1/8×, 1/4×, 1/2×, 1× MIC of LLY-507. The LLY-507 MIC for these S. aureus clinical isolates was 25 μM. The OD 600 of the bacterial cells was then measured by Bioscreen C (Turku, Finland) at 1-h intervals for 24 h. TSB without antimicrobials was used as the untreated control. Data are shown as mean ± SD, n = 3. Time-killing curve of LLY-507 against clinical MRSA (YUSA145) and the impact of LLY-507 on the growth curves of S. aureus planktonic cells. Bacterial cultures in the logarithmic growth phase (OD 600 = 0.6–0.8) were treated with 2× MIC of LLY-507, Vancomycin (Van), and <t>Linezolid</t> <t>(LZD)</t> separately (C). Bacterial cultures in the stationary phase (OD 600 > 3) were treated with 2× MIC of LLY-507, Vancomycin, and Linezolid, followed by overnight incubation (D). Bactericidal curves were plotted accordingly.
Enterococcus Faecalis Atcc 51299 Vancomycin Vanb, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/enterococcus faecalis atcc 51299 vancomycin vanb/product/ATCC
Average 99 stars, based on 1 article reviews
enterococcus faecalis atcc 51299 vancomycin vanb - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

Image Search Results


Examination of cell membrane permeability in VanA VRE (E. faecium BAA-2317) induced by compounds 1 and 2 (no induced permeability) versus 9a (induced permeability) at 10 μM (added at 5 min). Cell envelop permeability is indicated by an increase in fluorescence resulting from propidium iodide (PI) influx following compound administration.

Journal: The Journal of organic chemistry

Article Title: Guanidiniocarbonyl-Pyrrole (GCP) C- and N-Terminus Modifications of Vancomycin

doi: 10.1021/acs.joc.5c02760

Figure Lengend Snippet: Examination of cell membrane permeability in VanA VRE (E. faecium BAA-2317) induced by compounds 1 and 2 (no induced permeability) versus 9a (induced permeability) at 10 μM (added at 5 min). Cell envelop permeability is indicated by an increase in fluorescence resulting from propidium iodide (PI) influx following compound administration.

Article Snippet: 39 One day before experiments were run, cultures of vancomycin-resistant Enterococcus faecium (VanA VRE, ATCC BAA-2317) were inoculated and grown in an orbital shaker at 37 °C in 100% brain-heart infusion broth for 12 h. The above bacterial solution was subjected to a subculture to obtain fresh mid log phase bacterial cells (incubation time = 6 h).

Techniques: Membrane, Permeability, Fluorescence

Planktonic cells of MSSA SA113 (A) and MRSA YUSA145 (B) were treated with 1/16×, 1/8×, 1/4×, 1/2×, 1× MIC of LLY-507. The LLY-507 MIC for these S. aureus clinical isolates was 25 μM. The OD 600 of the bacterial cells was then measured by Bioscreen C (Turku, Finland) at 1-h intervals for 24 h. TSB without antimicrobials was used as the untreated control. Data are shown as mean ± SD, n = 3. Time-killing curve of LLY-507 against clinical MRSA (YUSA145) and the impact of LLY-507 on the growth curves of S. aureus planktonic cells. Bacterial cultures in the logarithmic growth phase (OD 600 = 0.6–0.8) were treated with 2× MIC of LLY-507, Vancomycin (Van), and Linezolid (LZD) separately (C). Bacterial cultures in the stationary phase (OD 600 > 3) were treated with 2× MIC of LLY-507, Vancomycin, and Linezolid, followed by overnight incubation (D). Bactericidal curves were plotted accordingly.

Journal: ACS Omega

Article Title: Inhibition of Growth and Biofilm Formation in Staphylococcus aureus by LLY-507

doi: 10.1021/acsomega.5c10668

Figure Lengend Snippet: Planktonic cells of MSSA SA113 (A) and MRSA YUSA145 (B) were treated with 1/16×, 1/8×, 1/4×, 1/2×, 1× MIC of LLY-507. The LLY-507 MIC for these S. aureus clinical isolates was 25 μM. The OD 600 of the bacterial cells was then measured by Bioscreen C (Turku, Finland) at 1-h intervals for 24 h. TSB without antimicrobials was used as the untreated control. Data are shown as mean ± SD, n = 3. Time-killing curve of LLY-507 against clinical MRSA (YUSA145) and the impact of LLY-507 on the growth curves of S. aureus planktonic cells. Bacterial cultures in the logarithmic growth phase (OD 600 = 0.6–0.8) were treated with 2× MIC of LLY-507, Vancomycin (Van), and Linezolid (LZD) separately (C). Bacterial cultures in the stationary phase (OD 600 > 3) were treated with 2× MIC of LLY-507, Vancomycin, and Linezolid, followed by overnight incubation (D). Bactericidal curves were plotted accordingly.

Article Snippet: Antibiotics LLY-507, Vancomycin (Van), and Linezolid (LZD) were bought from MCE.

Techniques: Control, Incubation